Use of anti-factor XII antibodies for treating or preventing hereditary angioedema

An angioedema, -FXII technology, applied in the direction of anti-coagulation factor immunoglobulin, antibody, anti-animal/human immunoglobulin, etc., can solve the problem that the effective treatment or prevention of anti-factor XII mAb is not clear

Pending Publication Date: 2022-07-15
シーエスエル イノベーション プロプライアタリー リミティド
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] Finally, it is unclear whether anti-factor X

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of anti-factor XII antibodies for treating or preventing hereditary angioedema
  • Use of anti-factor XII antibodies for treating or preventing hereditary angioedema
  • Use of anti-factor XII antibodies for treating or preventing hereditary angioedema

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0032] According to the invention, "anti-FXII antibodies" bind and inhibit the activated form of FXII, ie FXIIa-beta (beta-factor XIIa), but also bind FXII and FXIIa (alpha-factor XIIa).

[0033] An "antibody" in its broadest sense is a polypeptide comprising an immunoglobulin variable region that specifically recognizes an epitope on an antigen. The term "antibody" also includes antibody fragments that maintain the ability to bind FXIIa and FXII. Preferred antigen-binding fragments are Fab fragments, Fab' fragments, F(ab') 2 Fragments, Fv fragments, single chain antibodies, single chain Fv fragments, disulfide stabilized Fv proteins or dimers of single chain Fv fragments. Also included in the present invention are antibodies that are chimeric antibodies, humanized antibodies, murine antibodies or bispecific antibodies. Methods for producing these fragments and antibodies are well known in the art (see, eg, Harlow and Lane: Antibodies, A Laboratory Manual, Cold Spring Harbor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to an anti-FXII antibody for use in a method of treating or preventing hereditary angioedema (HAE) in a subject in which said antibody is administered subcutaneously to said subject.

Description

technical field [0001] The present invention relates to an anti-FXII antibody for use in a method of treating or preventing hereditary angioedema (HAE) in a subject, wherein the antibody is administered subcutaneously to the subject. Background technique [0002] Factor XII (Hagemann factor, FXII) is a serum glycoprotein with a molecular weight of about 80 kDa. In addition to self-activation by exposure to negatively charged surfaces, factor XII is additionally activated by proteolytic cleavage by kallikrein to form alpha-factor XIIa, which is then activated, for example, by pancreatic The protease is further converted to beta-factor XIIa (FXIIa-beta). Alpha-Factor XIIa consists of an N-terminal heavy chain of about 50 kDa containing a contact binding domain and a C-terminal light chain of about 28 kDa containing a catalytic center. The heavy and light chains are linked by disulfide bonds. FXIIa-beta is an approximately 30 kDa active form of FXII consisting of an intact l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/36A61P7/10A61K39/395
CPCC07K16/36A61K2039/505A61P7/10C07K2317/76C07K2317/90A61K2039/54A61K2039/545C07K2317/24C07K2317/21A61P7/00C07K2317/565
Inventor I·普拉克斯特D·帕瓦斯卡尔T·尤拉斯则克张莹
Owner シーエスエル イノベーション プロプライアタリー リミティド
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap